XML 55 R22.htm IDEA: XBRL DOCUMENT v3.23.3
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Disaggregation of Revenue Revenues recognized under the agreement were as follows (in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Revenue related to Kite agreement:
Recognition of license fee fixed consideration$5,388 $6,296 $17,938 $18,682 
Research services variable consideration108 619 1,097 875 
Total$5,496 $6,915 $19,035 $19,557 
Revenues recognized under the agreement were as follows (in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Revenue related to Novartis agreement:
Recognition of upfront license fee$— $7,582 $9,568 $23,222 
Research services— 2,028 2,611 6,211 
Total$— $9,610 $12,179 $29,433 
Revenues recognized under the agreement were as follows (in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Revenue related to Biogen agreement:
Recognition of license and other fixed consideration$— $7,306 $132,165 $21,918 
Cost-sharing payments for research services, net variable consideration— 2,107 2,684 8,740 
Total$— $9,413 $134,849 $30,658